Status:
COMPLETED
Itopride in Functional Dyspepsia:a Dose Finding Study
Lead Sponsor:
Royal Adelaide Hospital
Collaborating Sponsors:
Knoll Pharmaceuticals, Germany (now Abbott)
University Hospital, Essen
Conditions:
Functional Dyspepsia
Eligibility:
All Genders
18-95 years
Phase:
PHASE2
PHASE3
Brief Summary
This study aims to determine the efficacy and optimal dose of the prokinetic itopride for the treatment of patients with functional dyspepsia. The study will test in patients with functional dyspepsi...
Detailed Description
Treatment of patients with functional dyspepsia remains unsatisfactory. We will assess the efficacy of Itopride, a D2 antagonist with acetylcholinesterase effects in patients with functional dyspepsia...
Eligibility Criteria
Inclusion
- Diagnosis of functional dyspepsia (Rome criteria) -
Exclusion
- structural or biochemical abnormalities explaining the symptoms, concomitant symptoms of gastroesophageal reflux disease or irritable bowel syndrome dominating the clinical picture
- \-
Key Trial Info
Start Date :
December 1 2000
Trial Type :
INTERVENTIONAL
End Date :
January 1 2002
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00272103
Start Date
December 1 2000
End Date
January 1 2002
Last Update
May 4 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Essen
Essen, Hesse, Germany, 45122